EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Switch to English

11281	Sociétés
250681	Mots-clés
179366	Articles
136501	Communiqués

Accueil
Sociétés
EnVVeno Medical Corporation

COMMUNIQUÉ DE PRESSE

publié le 16/04/2024 à 15:00, il y a 2 années 6 mois

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années 6 mois

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années 6 mois

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
COMMUNIQUÉ DE PRESSE

publié le 09/04/2024 à 14:45, il y a 2 années 6 mois

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 7 mois

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 7 mois

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
COMMUNIQUÉ DE PRESSE

publié le 15/03/2024 à 14:00, il y a 2 années 7 mois

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 7 mois

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 7 mois

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
COMMUNIQUÉ DE PRESSE

publié le 06/03/2024 à 14:40, il y a 2 années 7 mois

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Les Echos

Publié le 05/11/2026 à 07:44, il y a 1 heure 31 minutes

Résultats d’ENGIE 9 mois 2026
Publié le 05/11/2026 à 07:44, il y a 1 heure 31 minutes

ENGIE 9M 2026 results
Publié le 05/11/2026 à 07:00, il y a 2 heures 15 minutes

Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Publié le 05/11/2026 à 07:00, il y a 2 heures 15 minutes

Eurazeo’s European asset management platform continues to gain momentum, driven by sustained international fundraising
Publié le 05/11/2026 à 07:00, il y a 2 heures 15 minutes

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/11/2026 à 08:00, il y a 1 heure 15 minutes

Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
Publié le 04/11/2026 à 23:10, il y a 10 heures 5 minutes

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Publié le 04/11/2026 à 23:00, il y a 10 heures 15 minutes

Avino Reports Q3 2026 Financial Results
Publié le 04/11/2026 à 23:00, il y a 10 heures 15 minutes

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Publié le 04/11/2026 à 22:15, il y a 11 heures

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Voir tout ACCESSWIRE

EQS Group

Publié le 05/11/2026 à 09:05, il y a 10 minutes

SINBON Links Executive Pay to ESG, Cuts Scope 1 and 2 Emissions 27.68% in 2025 Sustainability Report
Publié le 05/11/2026 à 09:03, il y a 12 minutes

u-blox sets a new size benchmark for antenna-integrated GNSS with the SAM-M11N
Publié le 05/11/2026 à 09:02, il y a 13 minutes

RHÖN-KLINIKUM AG reports results for the third quarter of 2026
Publié le 05/11/2026 à 09:00, il y a 15 minutes

Original-Research: ZEAL Network SE (von NuWays AG): BUY
Publié le 05/11/2026 à 09:00, il y a 15 minutes

Removal - Stadshypotek AB (PUBL)